Abiopharma

🔍 Li Yifan (Director)

Company: Hesai Group (HSAI)

Report Date: 2026-03-25

Detailed Transactions and Holdings:

• Acquired 157,000 shares of Restricted share units (Derivative)
  Date: 2026-03-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 157,000.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted share unit represents the contingent right to receive one (1) Class B ordinary share upon vesting.
• F2: These restricted share units were granted on March 25, 2026, and vest per annum in four equal installments over a 4-year period, starting from the first anniversary of May 31, 2026, subject to the reporting person's continued service through the applicable vesting date. The restricted share units do not have expiration dates.